Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 17/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15174141 | 1.00 | HCRTR1 (0.39) | HCRTR1HCRTR2CHRNA3MAPK1 | |
| SCHEMBL22761650 | 0.85 | HCRTR1 (0.39) | HCRTR1MAPK1 | |
| SCHEMBL1597983 | 0.80 | CHRNA3 (0.43) | CHRNA3MAPK1 | |
| SCHEMBL17009227 | 0.79 | HCRTR1 (0.42) | HCRTR1CHRNA3 | |
| SCHEMBL17009229 | 0.79 | HCRTR1 (0.42) | HCRTR1CHRNA3 | |
| SCHEMBL24381394 | 0.77 | HCRTR1 (0.42) | HCRTR1 | |
| SCHEMBL19207012 | 0.77 | HCRTR1 (0.42) | HCRTR1 | |
| SCHEMBL19256525 | 0.77 | HCRTR1 (0.42) | HCRTR1 | |
| SCHEMBL17009213 | 0.73 | PRPS1 (0.36) | HCRTR1HCRTR2MAPK1 | |
| SCHEMBL16031626 | 0.71 | CDK7 (0.51) | HCRTR1HCRTR2CHRNA3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9440982-B2 | Substituted prolines/piperidines as orexin receptor antagonists | EOLAS THERAPEUTICS, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| WO-2015123355-A1 | SUBSTITUTED PROLINES / PIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS | EOLAS THERAPEUTICS, INC. (US) | 2015-08-20 | — | — | WO | disclosed |
| US-20140364433-A1 | SUBSTITUTED PROLINES / PIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364433-A1 | SUBSTITUTED PROLINES / PIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OPRL1 | HCRTR1 2/4885HCRTR2 1/4885CHRNA3 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.